.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The Delhi High Court has reserved its judgment in the high-profile Daiichi-Fortis case after fifty intensive court sessions. Specifically, Japanese drugmaker Daiichi Sankyo is seeking to enforce a massive Singapore tribunal arbitral award against former Fortis promoters. Consequently, the legal representatives of both parties concluded their arguments before Justice Subramonium Prasad. This long-running corporate war has significant implications for regulatory compliance in India.
Originally, a Singapore tribunal issued the award a decade ago due to fraud allegations in the 2008 Ranbaxy Laboratories sale. However, the interest on this award has now swollen the total outstanding debt to over ₹5,200 crore. To recover this money, Daiichi wanted to prevent the Singh brothers from diluting their stake in Fortis Healthcare. Unfortunately, several financial institutions invoked and sold the pledged shares to recover separate debts. Therefore, the case has evolved into a complex three-way battle among lenders, Fortis, and the Singh brothers.
During the hearings, senior advocate Arvind Nigam argued that Fortis allowed deliberate asset dissipation under the former promoters. Specifically, he questioned the sale of 186 million shares, pointing out that promoter shares require regulatory approval. Additionally, Nigam asserted that the compliance officer must authorize any such share transfers under Sebi rules.
Conversely, Fortis Healthcare vehemently denied any liability for the share transfers. Furthermore, the counsel for Fortis claimed that Daiichi failed to use available legal tools to protect its interests. Because of this inaction, Fortis argues that Daiichi cannot hold the hospital chain responsible for the missing assets.
Q1: What is the main dispute in the Daiichi-Fortis case?
The dispute centers around Japanese drugmaker Daiichi Sankyo's effort to enforce a massive ₹5,200 crore arbitration award against the former promoters of Fortis Healthcare.
Q2: Why is Fortis Healthcare contesting the liability?
Fortis Healthcare argues that its compliance officer never approved any unencumbered share transfers. Furthermore, it asserts that Daiichi failed to use available legal tools earlier to protect its own interests.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The Delhi High Court has reserved its judgment in the multi-crore Daiichi-Fortis case, concluding fifty sessions of intense legal arguments....
2 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
